Buffett InvestorsNZX
Back
RYM.NZ

Ryman Healthcare Raised $1 Billion and the Stock Still Fell — Here's What Went Wrong

A $1 Billion Fix That Hasn't Fixed the Share Price

Ryman Healthcare (NZX: RYM) has done almost everything investors asked for. It raised $1 billion to repair the balance sheet. It slashed net debt from $2.56 billion to $1.59 billion. It delivered its first positive free cash flow in over a decade ($56.2 million). And it upgraded ORA sales guidance. Yet the stock sits at around $2.11 NZD — roughly 30% below the $3.05 capital raise price — and keeps falling. For Ryman Healthcare NZX stock investors, the question isn't whether the turnaround is happening. It's whether the market will ever believe in it.

Recent Performance: A Slow Bleed

The numbers are painful for anyone who participated in the capital raise:

  • •Current price: ~$2.11 NZD
  • •52-week range: $2.04 – $3.14 (prior high of $4.75 in late 2024)
  • •12-month decline: -24%
  • •Capital raise price: $3.05 (current price 30% below)
  • •Trading vs 200-day MA: -18% below

The retail segment of the $1 billion raise saw only 42% take-up from eligible shareholders — a damning signal of investor fatigue. The unsubscribed shares created a stock overhang that has depressed the price ever since.

Key Metrics at a Glance

  • •Market cap: ~$1.89 billion NZD
  • •P/E ratio: ~16x (trailing)
  • •EPS (forward consensus): $0.05 NZD
  • •Dividend: None (suspended, return mapped for FY2029)
  • •Net debt (post-raise): ~$1.59 billion (down from $2.56B)
  • •Gearing: 23.1% (down from 37.3%)
  • •H1 revenue: Up 13%
  • •H1 costs: Down 2%
  • •H1 free cash flow: +$56.2 million (first positive in a decade)
  • •Interest expense: $186 million annually
  • •Analyst consensus target: $3.26 NZD (Hold — implying 53% upside)

That $186 million annual interest bill tells you everything about why Ryman needed the capital raise. Even after cutting debt by nearly $1 billion, the company is paying a staggering amount in interest — more than its total reported EBITDA of $14.6 million. The balance sheet is healthier, but it's still heavy.

The $1 Billion Capital Raise: What It Achieved

Chairman Dean Hamilton called it a "decisive action to reset" the balance sheet. The numbers back that up:

  • •Net debt: $2.56B → $1.59B
  • •Gearing: 37.3% → 23.1%
  • •Medium-term gearing target: 20–30% (now achieved)

The raise comprised a $313 million institutional placement and a $688 million entitlement offer at $3.05 per share — a 22% discount to the theoretical ex-rights price and a 29% discount to the pre-announcement closing price. The steep discount was necessary to get it done, but it also heavily diluted existing shareholders.

ORA Sales: The Bright Spot

Occupation Right Agreement (ORA) sales — essentially the upfront payments residents make to enter Ryman villages — are the lifeblood of the business model. And they're improving:

  • •H1 FY2026 sales: 704 units (Q1: 337, Q2: 367 — showing sequential growth)
  • •Updated FY2026 guidance: 1,300–1,400 units (raised from 1,100–1,300)
  • •Average DMF on ORA sales: 28.8% (up from 20.7% in the prior period)

The higher deferred management fee (DMF) rate is significant — it means Ryman is extracting more value from each sale, reflecting embedded pricing model changes. Cost savings have also been upgraded to $50–60 million annualised.

The Demographic Tailwind Is Real — But Distant

New Zealand's population aged 75+ is projected to double over the next 20 years. That's demographic maths, not speculation. Ryman operates 47 retirement villages across NZ and Australia with roughly 14,000 residents. The demand runway is undeniable.

But here's the catch: the NZ property market is the transmission mechanism. If prospective residents can't sell their homes, they can't move into a Ryman village. The current slow property market is creating higher-than-normal inventory across the entire retirement village sector, suppressing cash flows even as underlying demand grows.

What to Watch

  • •FY2029 dividend return: Ryman's investor day mapped a path back to dividends by FY2029. That's three years away — a long time for income investors to wait.
  • •Property market recovery: A pickup in NZ house sales would directly accelerate ORA volumes and cash generation.
  • •Interest rate cuts: Lower rates would help on two fronts — reducing Ryman's interest burden and stimulating the housing market.
  • •May 15 earnings: The next results will show whether H2 ORA sales momentum is holding. Hitting the 1,300–1,400 unit guidance is critical.
  • •Net tangible asset backing: Ryman trades at just 0.5x NTA compared to 3x in its heyday. If the company can demonstrate sustained cash flow improvement, a re-rating toward book value would deliver substantial returns.
  • •New CEO execution: Naomi James needs "runs on the board" to rebuild credibility with a sceptical market.

The Bottom Line

Ryman Healthcare has taken the medicine — a massive capital raise, cost cuts, and improved ORA pricing are all moving in the right direction. The first positive free cash flow in a decade is a genuine milestone. But the stock's 30% decline below the raise price tells you the market wants proof, not promises. With analysts targeting $3.26 (53% upside) and demographics firmly on Ryman's side, the long-term case is compelling. The risk is that the turnaround takes years longer than anyone expects — and patient capital is a rare commodity.

*This article is for informational purposes only and does not constitute financial advice. Always conduct your own research or consult a licensed financial adviser before making investment decisions. Past performance is not indicative of future results.*